Diagnostic routes and time intervals for patients with colorectal cancer in 10 international jurisdictions; findings from a cross-sectional study from the International Cancer Benchmarking Partnership (ICBP)
- PMID: 30482749
- PMCID: PMC6278806
- DOI: 10.1136/bmjopen-2018-023870
Diagnostic routes and time intervals for patients with colorectal cancer in 10 international jurisdictions; findings from a cross-sectional study from the International Cancer Benchmarking Partnership (ICBP)
Abstract
Objective: International differences in colorectal cancer (CRC) survival and stage at diagnosis have been reported previously. They may be linked to differences in time intervals and routes to diagnosis. The International Cancer Benchmarking Partnership Module 4 (ICBP M4) reports the first international comparison of routes to diagnosis for patients with CRC and the time intervals from symptom onset until the start of treatment. Data came from patients in 10 jurisdictions across six countries (Canada, the UK, Norway, Sweden, Denmark and Australia).
Design: Patients with CRC were identified via cancer registries. Data on symptomatic and screened patients were collected; questionnaire data from patients' primary care physicians and specialists, as well as information from treatment records or databases, supplemented patient data from the questionnaires. Routes to diagnosis and the key time intervals were described, as were between-jurisdiction differences in time intervals, using quantile regression.
Participants: A total of 14 664 eligible patients with CRC diagnosed between 2013 and 2015 were identified, of which 2866 were included in the analyses.
Primary and secondary outcome measures: Interval lengths in days (primary), reported patient symptoms (secondary).
Results: The main route to diagnosis for patients was symptomatic presentation and the most commonly reported symptom was 'bleeding/blood in stool'. The median intervals between jurisdictions ranged from: 21 to 49 days (patient); 0 to 12 days (primary care); 27 to 76 days (diagnostic); and 77 to 168 days (total, from first symptom to treatment start). Including screen-detected cases did not significantly alter the overall results.
Conclusion: ICBP M4 demonstrates important differences in time intervals between 10 jurisdictions internationally. The differences may justify efforts to reduce intervals in some jurisdictions.
Keywords: epidemiology; gastrointestinal tumours; health policy; international health services; organisation of health services.
© Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY. Published by BMJ.
Conflict of interest statement
Competing interests: None declared.
Figures
Similar articles
-
Time intervals and routes to diagnosis for lung cancer in 10 jurisdictions: cross-sectional study findings from the International Cancer Benchmarking Partnership (ICBP).BMJ Open. 2019 Nov 27;9(11):e025895. doi: 10.1136/bmjopen-2018-025895. BMJ Open. 2019. PMID: 31776134 Free PMC article.
-
An investigation of routes to cancer diagnosis in 10 international jurisdictions, as part of the International Cancer Benchmarking Partnership: survey development and implementation.BMJ Open. 2016 Jul 25;6(7):e009641. doi: 10.1136/bmjopen-2015-009641. BMJ Open. 2016. PMID: 27456325 Free PMC article.
-
Diagnostic pathways for breast cancer in 10 International Cancer Benchmarking Partnership (ICBP) jurisdictions: an international comparative cohort study based on questionnaire and registry data.BMJ Open. 2022 Dec 15;12(12):e059669. doi: 10.1136/bmjopen-2021-059669. BMJ Open. 2022. PMID: 36521881 Free PMC article.
-
Variation in suspected cancer referral pathways in primary care: comparative analysis across the International Benchmarking Cancer Partnership.Br J Gen Pract. 2023 Jan 26;73(727):e88-e94. doi: 10.3399/BJGP.2022.0110. Print 2023 Feb. Br J Gen Pract. 2023. PMID: 36127155 Free PMC article. Review.
-
The patient, diagnostic, and treatment intervals in adult patients with cancer from high- and lower-income countries: A systematic review and meta-analysis.PLoS Med. 2022 Oct 20;19(10):e1004110. doi: 10.1371/journal.pmed.1004110. eCollection 2022 Oct. PLoS Med. 2022. PMID: 36264841 Free PMC article.
Cited by
-
Stage at diagnosis of colorectal cancer through diagnostic route: Who should be screened?World J Gastroenterol. 2024 Mar 14;30(10):1368-1376. doi: 10.3748/wjg.v30.i10.1368. World J Gastroenterol. 2024. PMID: 38596494 Free PMC article.
-
Measurement of clinical delay intervals among younger adults with colorectal cancer using health administrative data: a population-based analysis.BMJ Open Gastroenterol. 2022 Nov;9(1):e001022. doi: 10.1136/bmjgast-2022-001022. BMJ Open Gastroenterol. 2022. PMID: 36410773 Free PMC article.
-
Guideline interval: A new time interval in the diagnostic pathway for symptomatic cancer.Cancer Epidemiol. 2021 Aug;73:101969. doi: 10.1016/j.canep.2021.101969. Epub 2021 Jun 19. Cancer Epidemiol. 2021. PMID: 34157609 Free PMC article.
-
The Timeliness of Drug Therapy in Colorectal and Prostate Cancer in Antigua and Barbuda: The Role of Disease Stage.Healthcare (Basel). 2025 Apr 16;13(8):915. doi: 10.3390/healthcare13080915. Healthcare (Basel). 2025. PMID: 40281864 Free PMC article.
-
Factors associated with diagnostic and treatment intervals in colorectal cancer: A linked data study.Int J Cancer. 2025 Aug 15;157(4):687-697. doi: 10.1002/ijc.35414. Epub 2025 Mar 13. Int J Cancer. 2025. PMID: 40079691 Free PMC article.
References
-
- Coleman MP, Forman D, Bryant H, et al. . Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet 2011;377:127–38. 10.1016/S0140-6736(10)62231-3 - DOI - PMC - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases